265 related articles for article (PubMed ID: 25555319)
1. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.
Dasta JF; Pilon D; Mody SH; Lopatto J; Laliberté F; Germain G; Bookhart BK; Lefebvre P; Nutescu EA
Thromb Res; 2015 Feb; 135(2):303-10. PubMed ID: 25555319
[TBL] [Abstract][Full Text] [Related]
2. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
LaMori JC; Shoheiber O; Mody SH; Bookhart BK
Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.
Mahan CE; Borrego ME; Woersching AL; Federici R; Downey R; Tiongson J; Bieniarz MC; Cavanaugh BJ; Spyropoulos AC
Thromb Haemost; 2012 Aug; 108(2):291-302. PubMed ID: 22739656
[TBL] [Abstract][Full Text] [Related]
5. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
6. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
[TBL] [Abstract][Full Text] [Related]
7. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.
Spyropoulos AC; Lin J
J Manag Care Pharm; 2007; 13(6):475-86. PubMed ID: 17672809
[TBL] [Abstract][Full Text] [Related]
8. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
[TBL] [Abstract][Full Text] [Related]
9. A cost-analysis model for anticoagulant treatment in the hospital setting.
Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
[TBL] [Abstract][Full Text] [Related]
10. The Incidence and Economic Burden of In-Hospital Venous Thromboembolism in the United States.
Shahi A; Chen AF; Tan TL; Maltenfort MG; Kucukdurmaz F; Parvizi J
J Arthroplasty; 2017 Apr; 32(4):1063-1066. PubMed ID: 27866951
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of hospitalization costs for 278 venous thromboeboembolism patients with health insurance in China].
Wu JJ; Yang L
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 45(3):437-42. PubMed ID: 23774924
[TBL] [Abstract][Full Text] [Related]
12. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
[TBL] [Abstract][Full Text] [Related]
13. [Clinical analysis of 20 pregnant women with venous thromboembolic disease].
Sun P; Dong DN
Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):911-6. PubMed ID: 22333281
[TBL] [Abstract][Full Text] [Related]
14. Inpatient and outpatient occurrence of deep vein thrombosis and pulmonary embolism and thromboprophylaxis following selected at-risk surgeries.
Amin AN; Lin J; Thompson S; Wiederkehr D
Ann Pharmacother; 2011 Sep; 45(9):1045-52. PubMed ID: 21862717
[TBL] [Abstract][Full Text] [Related]
15. Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis.
Lang K; Patel AA; Munsell M; Bookhart BK; Mody SH; Schein JR; Menzin J
J Thromb Thrombolysis; 2015 May; 39(4):434-42. PubMed ID: 25079971
[TBL] [Abstract][Full Text] [Related]
16. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
[TBL] [Abstract][Full Text] [Related]
17. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
[No Abstract] [Full Text] [Related]
18. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
Gourzoulidis G; Kourlaba G; Kakisis J; Matsagkas M; Giannakoulas G; Gourgoulianis KI; Vassilakopoulos T; Maniadakis N
Clin Drug Investig; 2017 Sep; 37(9):833-844. PubMed ID: 28608312
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulant therapy after venous thromboembolism and 10-year mortality.
Larsen TB; Lip GY; Gorst-Rasmussen A
Int J Cardiol; 2016 Apr; 208():72-8. PubMed ID: 26828386
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.
MacDougall DA; Feliu AL; Boccuzzi SJ; Lin J
Am J Health Syst Pharm; 2006 Oct; 63(20 Suppl 6):S5-15. PubMed ID: 17032933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
